The bottleneck in AZT activation

@article{Lavie1997TheBI,
  title={The bottleneck in AZT activation},
  author={A. Lavie and I. Schlichting and I. Vetter and Manfred Konrads and J. Reinstein and R. Goody},
  journal={Nature Medicine},
  year={1997},
  volume={3},
  pages={922-924}
}
Nucleoside-based inhibitors of reverse transcriptase were the first drugs to be used in the chemotherapy of AIDS. After entering the cell, these substances are activated to their triphosphate form by cellular kinases, after which they are potent chain terminators for the growing viral DNA (ref. 1). The two main factors limiting their efficacy are probably interrelated. These are the insufficient degree of reduction of viral load at the commencement of treatment and the emergence of resistant… Expand
Review Nucleoside and nucleotide inhibitors of HIV-1 replication
TLDR
The NRTIs currently in clini- cal trials and new developments in this area are re- viewed, which are highly efficient in slowing down viral replication and are used in combination regimens. Expand
Nucleoside and nucleotide inhibitors of HIV-1 replication
TLDR
The NRTIs currently in clinical trials and new developments in this area are reviewed and improved discrimination of a nucleotide analogue relative to the natural substrate or increased phosphorolytic cleavage of an analogue-blocked primer is reviewed. Expand
A critical analysis of the pharmacology of AZT and its use in AIDS.
TLDR
A critical analysis of the presently available data shows that no evidence of AZT possessing an anti-HIV effect exists, an outcome not unexpected given the pharmacological data on AZT. Expand
Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses.
TLDR
The lessons learned are that each nucleoside analog should be treated as a unique molecule since any structural modification, including a change in the enantiomeric form, can affect metabolism, pharmacokinetics, efficacy, toxicity and resistance profile. Expand
Human and viral nucleoside/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties.
TLDR
The structural and enzymatic properties of the enzymes that carry out the activation of analogs used in therapy against human immunodeficiency virus and against DNA viruses such as hepatitis B, herpes and poxviruses are reviewed. Expand
Possible New Reaction Mechanisms of Dideoxynucleosides as Anti-Aids Drugs
Evidence is presented that a major class of drugs, the dideoxynucleosides (ddNs) and nucleoside/nucleotide analogues, may inhibit the symptoms of acquired immunodeficiency syndrome (AIDS) byExpand
HIV-1 reverse transcriptase inhibitors
TLDR
This study focuses on RT inhibitors approved by the US Food and Drugs Administration or in phases II and III clinical trials, and reviews the mechanism of action, the resistance mechanisms selected by the virus, and the side effects of the drugs. Expand
HIV-1 Polymerase Inhibition by Nucleoside Analogs: Cellular- and Kinetic Parameters of Efficacy, Susceptibility and Resistance Selection
TLDR
This model correctly predicts for HIV-1 that resistance against nucleoside analog reverse transcriptase inhibitors (NRTIs) can be conferred by decreasing their incorporation rate, increasing their excision rate, or decreasing their affinity for the polymerase enzyme. Expand
Activation Pathway of a Nucleoside Analog Inhibiting Respiratory Syncytial Virus Polymerase.
TLDR
The activation pathway of ALS-8112 is identified and it is shown it is unlike other antiviral cytidine analogs, highlighting an exciting potential to optimize nucleoside analogs based on the second activation step and increased attention toward nucleosid diphosphate and triphosphate prodrugs in drug discovery. Expand
Mechanisms of clinical resistance by HIV-I variants to zidovudine and the paradox of reverse transcriptase sensitivity.
TLDR
The occurrence, characterization and ramification ofAZT resistance in HIV-positive individuals will be discussed in the context of genotypic and phenotypic analyses of AZT-resistant viruses and reverse transcriptases. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 16 REFERENCES
3′-Azidothymidine (Zidovudine) Inhibits Glycosylation and Dramatically Alters Glycosphingolipid Synthesis in Whole Cells at Clinically Relevant Concentrations (*)
TLDR
AZT treatment dramatically alters the pattern of glycosphingolipid biosynthesis, nearly abolishing ganglioside synthesis at clinically relevant concentrations (1-5 μM), and suppresses the incorporation of both sialic acid and galactose into proteins, suggesting that the myelosuppressive effects of AZT in vivo are due to inhibition of protein and/or lipid glycosylation and not to effects on chromosomal DNA replication. Expand
Factors contributing to the inhibition of HIV reverse transcriptase by chain‐terminating nucleotides in vitro and in vivo
TLDR
It is concluded that potent inhibition of HIV‐reverse transcriptase activity under typical in vitro and in vivo conditions arises from different features of the interaction of chain terminators with the enzyme. Expand
Metabolism of 3'-azido-3'-deoxythymidine (AZT) in human placental trophoblasts and Hofbauer cells.
TLDR
The intracellular phosphorylation of AZT in two major cell types of the placenta, namely trophoblasts and Hofbauer cells, found that AZT monophosphate was the major phosphorylated AZT metabolite, while AZT diphosphate (AZTDP) and AZTTP constituted less than 4% of the intrace Cellular AZT pool. Expand
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.
TLDR
The results reported here suggest that azidothymidine is nonselectively phosphorylated but that the triphosphate derivative efficiently and selectively binds to the HIV reverse transcriptase. Expand
Interaction of fluorescently labeled dideoxynucleotides with HIV-1 reverse transcriptase.
TLDR
The results obtained suggest that potent inhibition of reverse transcriptase activity in in vitro assays results from formation of a slowly dissociating complex between the enzyme and chain-terminated primer/template complexes. Expand
Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells.
TLDR
The results strongly suggest that AZTMP is responsible for a major part of the growth inhibitor effects, while AZTTP mainly mediates the antiviral activity of AZT. Expand
Interactions of azidothymidine triphosphate with the cellular DNA polymerases alpha, delta, and epsilon and with DNA primase.
TLDR
It is proposed that the repair of 3'-azidothymidine-containing primers might become rate-limiting for the process of DNA replication in cells that have been treated with azidothamidine triphosphate. Expand
Selective action of 3'-azido-3'-deoxythymidine 5'-triphosphate on viral reverse transcriptases and human DNA polymerases.
TLDR
The selective incorporation of the chain-terminating nucleotide by the viral reverse transcriptases appears to be a molecular basis for the positive therapeutic index of 3'-azido-3'-deoxythymidine. Expand
Effects of 3'-azido-3'-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells.
TLDR
The effects of 3'-azido-3'-deoxythymidine (AZT) on the deoxynucleotide pools of three human cell lines, HL-60, H-9, and K-562, were determined and the concentration of thymidine, and to a lesser extent deoxyuridine, increased in the media of treated cells. Expand
3'-azido-3'-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNA
TLDR
A 3'-exonuclease(s) that excised 3'-azido-3'-deoxythymidine (AZT) monophosphate ( AZTMP) from the 3' terminus of DNA was partially purified from two human cell lines to trigger the toxicity of AZT by impairing the repair ofAZTMP-terminated DNA. Expand
...
1
2
...